Another concern is that inhibition or knockdown of PERK in melanoma cells made them hard to survive after ERS and resulted in immunogenic cell death (ICD) (Mandula et al. 2022), which exhibited the potential of targeting ERS in immunotherapy. Here, EIF2AK3 is linked to melanoma.